Asia’s super-aging societies are sparking a boom in high-end longevity clinics—even if ‘public enthusiasm’ is outpacing the science

A new kind of business—blending hospitality, technology, and traditional practices—is promising to extend not just lifespan, but also 'healthspan'.

A nondescript wooden door in Singapore’s central business district leads to an amiable concierge and a cup of warm tea. Customers at the Rekoop clinic swap their office clothes for scrubs and a pair of bedroom slippers, then are whisked through a series of wellness treatments: red light therapy, lymphatic massages, hyperbaric oxygen therapy, and others. 

Clinics like this are part of a new wave of longevity offerings taking Asia’s luxury hospitality sector by storm. 

By 2030, one in four Asians will be over 60. Japan, South Korea, Taiwan, and Singapore have already crossed the threshold into “super-aged” status. Thailand and Malaysia are fast behind. Now, a $4.6 trillion industry is stepping in to meet aging Asians’ desire to remain healthy and independent into their old age.

For now, it’s the wellness and hospitality industry that’s capturing most of the market. Last October, METT Singapore inked a partnership with The Longevity Suite, a European anti-aging clinic, to open its first Asian branch within the hotel. Luxury hotel chain Capella also announced its first venture into “wellness-integrated branded residences” which boast a wellness concierge and vitality checkpoints for residents to monitor their biometrics; the first project is a 262-unit development in Bangkok, Thailand.

A new kind of business—one that blends hospitality, technology, and traditional healing practices—is promising to extend not just lifespan, but also ‘healthspan,’ the number of years lived in good health. “People increasingly want to remain healthy, productive and independent, rather than simply living longer,” Andrea Maier, a gerontology professor at the National University of Singapore (NUS), tells Fortune.

Rising incomes across Asia are helping to drive demand for healthcare. As incomes rise, the newly-rich can devote more money to non-essential health, wellness, and preventive services, as well as advanced medical technologies and better insurance options. 

The COVID-19 pandemic also catalyzed a shift in consumer values. “Many people started treating luxury as something to do with health and well-being,” says Lau Kong Cheen, a marketing expert from the Singapore University of Social Sciences (SUSS). “They realized that they couldn’t take life for granted, and the cars, watches and handbags they buy would amount to nothing if they don’t have good health.”

Yet given the nascence of the industry, some experts worry that wellness clinics are overpromising on their ability to reverse aging. “Longevity is a complex field, and facilities need qualified experts if they want to make serious health claims,” says Zilmiyah Kamble, a senior lecturer at Singapore’s James Cook University. “In reality, it’s difficult to deliver measurable long-term health outcomes over short treatment stints.”

What’s a longevity clinic?

Many longevity clinics offer a suite of tech-enabled treatments, from cryotherapy and hyperbaric oxygen treatments to red light therapy and dry floats. Yet many purveyors of these treatments suggest their origins hark back thousands of years, to the ancient Egyptians or Greeks. 

“Hot and cold therapies have been used for ages,” says Nort Janssen, the CEO of The Longevity Suite Asia. “The fact that we now have saunas and a big freezer that is -87 degrees Celcius just makes them a bit easier to perform.”

There’s also a social element. Communal bathhouses like the Ice Bath Club and Nowhere Baths have sprung up in Asian financial hubs like Singapore and Hong Kong, where health-conscious millennial and Gen Z consumers pay hefty sums for a chilly soak. 

“People are constantly talking about it on Instagram and TikTok,” Janssen says, adding that in a hot country like Singapore, a cold plunge has “added appeal.”

The longevity boom in Asia is also taking on a local flavor, adding elements from practices like traditional Chinese medicine and Ayurvedic healing practices. 

“In the U.S., longevity is often linked to biohacking, wearables, supplements and performance optimization,” notes Ada Lo, an associate professor in hospitality and hotel management at the Hong Kong Polytechnic University (PolyU). “But in Asia, longevity is framed more holistically, combining modern diagnostics with traditional healing, meditation, food-as-medicine and high-touch hospitality.”

New resort brands like Blossom House by China’s Huazhu Group often integrate core tenets of TCM like shiliao (food therapy) into their programming. Janssen, too, is introducing TCM and Ayurvedic elements in The Longevity Clinic’s APAC branches. “We won’t just do blood tests and western diagnostics—we’ll have Ayurvedic masters to do dosha mapping, and TCM masters studying the flow of vital energy, or Qi, in your body,” he explains.

Despite the buzz, such therapies have only proven effective for some. A landmark 2025 study published in PLOS One found that hot and cold plunges speed up post-exercise muscle recovery in men, but not in women.

The broader biotechnology sector is also exploring new biomedical treatments that might have implications for longevity. Studies of GLP-1 drugs in particular show improvements on a range of health indicators, including lower blood glucose levels, reduced rates of cardiovascular death, and slower progression of chronic kidney disease.

“There are signals that GLP-1s could be the first true longevity drug,” Alex Zhavoronkov, founder of AI drug discovery firm Insilico Medicine said at the Fortune Innovation Forum last November. 

‘Public enthusiasm has outpaced scientific validation’

Many longevity treatments currently on the market, whether they rely on traditional techniques or supposed novel biotechnology, don’t yet have the same scientific backing as more accepted medical interventions. 

“Public enthusiasm has outpaced scientific validation,” Maier, who runs her own longevity clinic, explains. “This creates tremendous opportunities, but also considerable risks if interventions are marketed before robust evidence exists.” She points to treatments like red light therapy and cold exposure, where the evidence on whether they extend healthspan is still sparse. 

Even more advanced treatments, like stem cell therapy, present questions. “NAD+ biology is scientifically fascinating, but evidence supporting routine supplementation in healthy adults remains limited,” Maier explains. She cites possible side-effects to stem cell therapies like immune rejection and teratoma tumors.

Longevity packages are also expensive. Chi Longevity, co-founded by Maier, offers packages ranging from 4,250 Singapore dollars ($3,290) to 18,000 Singapore dollars ($13,920). The most expensive package includes blood tests and gene panels, physical and cognitive assessments, lifestyle appointments with dieticians, physicians, health coaches and psychologists, and the promise of a re-test after six months. 

“It’s probably popular to say that we want to make things accessible,” Janssen of The Longevity Suite says. “But to be fair, we’re serving the ultra-high-net-worth market.”

GLP-1 drugs, too, are very costly. Ozempic is typically priced between $350 and $500 per month, while Wegovy sets users back $1,350 per month, according to manufacturer Novo Nordisk.

“If longevity becomes only a luxury product, it widens the gap between those who can afford preventive wellness and those who cannot,” Kamble says.

Most insurers, like China’s Ping An, and Hong Kong-based AIA and Prudential, also do not fund elective longevity treatments. Critical illness plans typically cover only treatments for diagnosed diseases and specific medical conditions. 

Yet regional health insurers are still thinking about longevity. “Traditional passive healthcare and post-incident claims settlements alone are no longer sufficient to meet the health needs arising from longevity,” a Ping An spokesperson told Fortune. “What’s needed is more proactive health management, with earlier intervention to delay functional decline, reduce the risk of disability and help more people maintain good health over a longer life course.”

How, then, should Asia navigate this desire for longevity? Ironically, the interventions with the strongest scientific evidence for extending healthspan–physical activity, nutrition, sleep, vaccination, mental wellbeing and detecting disease early–tend to be the cheapest. 

“They sound boring,” Maier says, “but when done with precision, they’re hugely effective.”

This story was originally featured on Fortune.com